Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (411-420 of 471) with videos related to

Pageof 48
Sort By:
Circulation|February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
European Heart Journal|May 30, 2015
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patientsAkshay S Desai, John J V McMurray, Milton Packer, et al.
American Heart Journal|February 3, 2009
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Adrian F Hernandez, Christopher M O'Connor, Randall C Starling, et al.
European Journal of Heart Failure|August 10, 2013
Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering propertiesDaniela Dobre, Jeffrey S Borer, Kim Fox, et al.
European Heart Journal|August 2, 2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HFPardeep S Jhund, Michael Fu, Edmundo Bayram, et al.
European Heart Journal|June 26, 2023
Stroke in patients with heart failure and reduced or preserved ejection fractionMingming Yang, Toru Kondo, Jawad H Butt, et al.
Journal of the American College of Cardiology|January 10, 2019
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and WomenPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
European Journal of Heart Failure|December 30, 2021
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HFJames P Curtain, Alice M Jackson, Li Shen, et al.
Journal of the American College of Cardiology|September 25, 2024
Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HFShingo Matsumoto, Li Shen, Alasdair D Henderson, et al.
European Journal of Heart Failure|April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HFIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
Pageof 48

Showing results (411-420 of 471) with videos related to

Sort By:
Pageof 48
Circulation|February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
European Heart Journal|May 30, 2015
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patientsAkshay S Desai, John J V McMurray, Milton Packer, et al.
American Heart Journal|February 3, 2009
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Adrian F Hernandez, Christopher M O'Connor, Randall C Starling, et al.
European Journal of Heart Failure|August 10, 2013
Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering propertiesDaniela Dobre, Jeffrey S Borer, Kim Fox, et al.
European Heart Journal|August 2, 2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HFPardeep S Jhund, Michael Fu, Edmundo Bayram, et al.
European Heart Journal|June 26, 2023
Stroke in patients with heart failure and reduced or preserved ejection fractionMingming Yang, Toru Kondo, Jawad H Butt, et al.
Journal of the American College of Cardiology|January 10, 2019
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and WomenPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
European Journal of Heart Failure|December 30, 2021
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HFJames P Curtain, Alice M Jackson, Li Shen, et al.
Journal of the American College of Cardiology|September 25, 2024
Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HFShingo Matsumoto, Li Shen, Alasdair D Henderson, et al.
European Journal of Heart Failure|April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HFIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
Pageof 48